Clearside Biomedical to Report Second Quarter 2018 Financial Results on August 8, 2018 – Conference Call to Follow
August 01 2018 - 8:00AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing treatments that restore and
preserve vision for people with serious eye diseases, announced
today that its second quarter 2018 financial results will be
released at approximately 7:00 a.m. ET on Wednesday, August 8,
2018. Following the release, Clearside will host a live
conference call and webcast at 8:30 a.m. ET to discuss its
financial results and provide a general business and strategic
review.
The live webcast and a replay may be accessed by
visiting the “Investor Relations” section at www.clearsidebio.com.
Alternately, please call (844) 263-8310 (U.S.) or (213)
358-0959 (international) to participate in the live conference
call. The conference ID number for the live call is
6390517. Please dial in approximately 10 minutes prior to the
call. An archive of the webcast will be available until
September 8, 2018.
About Clearside
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing treatments that
restore and preserve vision for people with serious eye
diseases. Clearside’s proprietary suprachoroidal treatment
approach offers unprecedented access to the back of the eye where
sight-threatening disease often occurs. The company’s unique
platform for eye disease treatments is inherently flexible and
intended to work with established medicines, new formulations of
medicines, as well as future innovations. Clearside’s
pipeline includes advanced and pre-clinical product candidates in
diseases where macular edema is a common complication, including
uveitis, retinal vein occlusion (“RVO”) and diabetic macular edema
(“DME”). Clearside’s most advanced program is in
non-infectious uveitis and it expects to submit a New Drug
Application to the U.S. Food and Drug Administration for use of
suprachoroidal CLS-TA for the treatment of macular edema associated
with non-infectious uveitis by the end of 2018. The company
is also conducting two ongoing Phase 3 trials of suprachoroidal
CLS-TA with an intravitreal anti-VEGF agent in patients with
RVO. In addition, Clearside recently announced positive
topline results from a Phase 2 clinical trial of suprachoroidal
CLS-TA used with EYLEA® (aflibercept) in patients with DME, and is
continuing to analyze additional data from the trial as it becomes
available. Clearside is headquartered in Alpharetta,
GA. For more information, please visit
http://www.clearsidebio.com. Follow @clearsidebio on Twitter
and Linkedin.
Contacts:
Stephen KilmerInvestor Relations(678)
430-8206stephen.kilmer@clearsidebio.com
Charles DeignanChief Financial Officer(678)
270-4005charlie.deignan@clearsidebio.com
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Apr 2023 to Apr 2024